Q2 Earnings Estimate for MBRX Issued By HC Wainwright

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Moleculin Biotech in a report released on Monday, June 9th. HC Wainwright analyst S. Nik forecasts that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q3 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.66) EPS and FY2026 earnings at ($1.35) EPS.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.02. During the same quarter in the previous year, the firm earned ($2.02) EPS.

Other analysts also recently issued research reports about the company. Wall Street Zen upgraded Moleculin Biotech to a “sell” rating in a research note on Wednesday, March 26th. Maxim Group raised Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Tuesday, March 25th.

Moleculin Biotech Stock Down 1.2%

Shares of NASDAQ MBRX opened at $0.66 on Wednesday. The company has a 50 day simple moving average of $0.91 and a two-hundred day simple moving average of $1.37. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $4.90.

Institutional Trading of Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC lifted its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,250,000 shares of the company’s stock after buying an additional 932,414 shares during the period. Armistice Capital LLC owned about 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.